Abstract: An anticancer "magic bullet" should have both efficacy and specificity parts. We have used an effective Apoptosis I nducer t o t rigger t he apoptosis. A lpha-fetoprotein w as us ed t o de liver A poptosis I nducers s pecifically t o cancer cells. The AFP-AI complex inhibited tumor growth in mice, enlarged mice life survival and has shown a 50% response in patients with metastatic colorectal cancer.
INTRODUCTION
Cancer is the proliferation/apoptosis overbalance. Proliferation a nd apoptosis a re di fferent s ystems and a re us ed completely di fferently li ke t he c ar ga s a nd bra ke s ystems ( Fig. 1) . Traditional anticancer drugs mainly aim at suppressing proliferation by any mean (more than 700 molecular targeted ag ents ar e cu rrently in tr ials), b ut d irectly a ctivating apoptosis is a better idea (less than 30 agents in trials) [1, 2] . Apoptosis is responsible for recycling billions of cells everyday in the body. Cancer cells accumulate m utations in both proliferation and apoptosis systems, but crucial mutations in the apoptosis system h elp them to avoid the natural suicidal pathway. T o ove rcome the broke n apoptosis elements, t he drug should act "downstream" of m utated apoptosis cascade elements ( Fig. 1) . To trigger the apoptosis, a drug ne eds to: 1. be specific to cancer cell, 2 . provide d irect Apoptosis Inducer (AI) internalization, 3. Use AI acting "downstream" of the broke n a poptosis c ascade element. F or t hose purpos es, several combinations can b e obta ined w ith n anoparticles, immunoliposomes, cell-penetrating peptides, small molecule AIs, etc. We have prepared a non-covalent complex of alphafetoprotein ( AFP) th at c an s pecifically d eliver A I to cancer cells and act on functional executive apoptosis elements.
EFFECTIVE KILLING: DON'T REINVENT THE WHEEL -FIX THE BRAKES
Many cancer drugs are not optimal and often ineffective since th ey ai m at the tar gets w ithin th e p roliferation s ystem (for example, D NA) which m ight not lead to th e cancer cell death due to a frequent mutation of t he p53 prot ein or ot her mutations in apoptosis pathways (Fig. 1) [3] .
The probl em of s pecific a nd e ffective e limination of definite cells in the body is already solved in Nature. Cytotoxic T lymphocytes (CT L), for e xample, us e t his mechanism. They first recognize wrong cell by membrane antigens and then us e perforin for t he internalization of gra nzyme B that activates caspases -th e f inal en zymes w ithin the ap optosis cascade (Fig. 1) [4] . Granzyme B is a d irect apoptosis inducer and is not dependent on " upstream" cancer cell mutations such as p53 a nd o thers. F or this re ason, CTL c an *Address correspondence to this author at the Constab Pharmaceutical Inc., MaRS Centre, Toronto, Canada; E-mail: vpak@constabpharma.com "fix the brakes" meaning they are using undamaged apoptosis el ements in side cancer ce lls (Fig. 1) . Tr aditional ch emotherapy targeting proliferation system elements (for example, doxorubicin: DNA) c an be a ttributed to i ndirect a poptosis inducers because it can lead to the following next activation of a poptosis. Non re pairable DNA m utations caused by doxorubicin lead to p53-dependant apoptosis in normal cells. Direct a poptosis i nducers on t he oppos ite, t rigger a poptosis themselves. The closer direct apoptosis inducer can act on a late ap optosis event less ch ances are th at cancer c ell m utations m ight p revent its a ction. The id eal s ituation is that caspase activators s uch a s th e P AC-1 m olecule, b eing th e last t arget in the cascade, w ill activate p rocaspase 3 thus triggering c aspase 3 a ctions a nd de monstrate an e ffective anticancer action [5] .
We tried to copy the effective natural CTL "know-how" to find and kill cancer cells by combining our lessons learned from CTL and using the known biological tools.
A m embrane i s c onsidered be ing t he edge be tween l ife and death. Damage in the membrane of m itochondria, endoplasmic re ticulum, l ysosome or pe roxisome c an l ead t o t he whole eukaryotic cell death. The membrane of m itochondria was chosen as a target because mitochondrion is a "point of no r eturn" in th e in trinsic ap optosis p athway [ 6] . W e h ave used prove n a poptosis i nducers a cting on m itochondrion such as a tractyloside, be tulinic acid [7, 8] a nd an endoplasmic reticulum apoptosis inducer thapsigargin [9] . Within the intrinsic a poptosis pathway, t he m itochondrion a cts downstream of the p53 prot ein. P53 is inactive in more that 50 % of c ancer c ells a nd oft en l eads t o m ulti drug re sistance (MDR) [10] . Atractyloside was shown to induce apoptosis in p53-unfunctional HuH-7 cancer cells [11] .
Since m any of t he agents do not cross the p lasma membrane, w e h ad to u se ag ents combined to a s pecial d elivery system in order to induce their internalization of those agents with a s pecial d elivery s ystem. Moreover, this d elivery s ystem s hould have t he ability t o select c ancer cells a nd avoid healthy tissues.
SPECIFIC DELIVERY
AFP may be responsible for embryotoxic and teratogenic action of s ome drugs , pol lutants a nd c hemicals. One of t he explanations of t his phenomenon is that AFP has the ability to ta ke toxins from m other's b lood a nd bri ng i t t o the embryo [1 2]. In s uch c ase, AF P s hould c ompete wit h t he mother's a lbumin for bi nding t o t he t oxin. Am ong m any other s ubstrates AF P ha s the s trongest bi nding a ffinity to polyunsaturated f atty a cids (P UFA). Afte r t he AF P-PUFA complex endocytosis by e mbryo cells the PUFA is internalized [13] . W e ha ve s ubstituted t he P UFA i n t he porc ine AFP-PUFA complex for a tractyloside and have obtained the natural effective delivery system for the powerful direct AI.
A lot of AFP conjugates were used for the targeted delivery o f d ifferent to xins to cancer cells, f or ex ample, A FPesperamicin A1 [14] .
We use the non-covalent complex that is closer to natural protein form and wil l no t provoke i mmune a ttack a s A FP conjugates can pos sibly do. In t his c ase we can r ely on t he pharmacokinetic da ta obta ined for na tural hum an AF P i njectable drug na med " Alfetin" t hat wa s s hown t o ha ve 3-5 days of half-life time in the human body [15] . Pre-binding of AFP (MW=70 kDa) to atractyloside (MW=0.8 kDa) in 1:1-2 molar r atio pos sibly do not change pure AF P pha rmacokinetic profile.
DISCUSSION
AFP i s a known onc ology m arker [16, 17, 18] . F or t he addressed de livery of t he AI, we have us ed AF P which ha s highly s pecific re ceptors re -expressed on the m ajority o f cancer cells [19] and is up taken by them [20] . AFP-mediated de livery of di oxin to c ancer c ells h aving AFP re ceptor (AF PR) wa s 200-1400 t imes more effective than di oxin a lone [12] . T he e nvironmental t oxin di oxin is itself carcinogenic [21] a nd is not a direct AI, so its anticancer application is problematic.
An i njectable complex of A FP w ith an antifungal drug amphotericin B wa s us ed t o t reat c ancer [22, 23] . Am photericin B does not act on mitochondrion [24] and hence is not as effective as direct AI.
We non-c ovalently bound AF P to a prove n di rect AIatractyloside which is toxic to the mitochondria (Fig. 1) . The AFP-AI co mplex ( Aimpila™) w as p repared as d escribed i n [25] . B riefly, t he porc ine e mbryo bl ood a nd a mniotic f luid were collected, puri fied a nd c oncentrated wit h 50 kD a MWCO ult rafiltration m odule, A FP wa s extracted by but anol, diafiltrated, complexed with atractyloside in 1:1-2 molar ratios and lyophilized.
The Aimpila™ (0.02 mg in 0.2 ml of oil/day) being given orally ha s s hown t o i nhibit t umor growt h i n t he m ice p388 leucosis m odel by 85% wi thin 25 da ys a nd e nlarged m ice life survival by 36% [25] .
The p388 l eucosis m odel for Ai mpila™ in m ice wa s taken because was used before for AFP-drug conjugates testing [14] . AFP i s known t o be re sistant t o prote olytic attack from enzymes such as trypsin [26] . The oral route for peptide and protein drug de livery for s everal drugs wa s shown be fore [27] . Th e p rotein o f the s imilar s ize as A FP -r ecombinant interferon -i s a bsorbed from re ctal s uppositories a nd wa s effective t o s uppress re plication of he patotrophic vi ruses in the li ver of c hildren wit h he patitis B a nd C [28] . T he oil added t o t he drug form ulation proba bly he lped pre venting Aimpila™ from d egradation i n GI t ract a nd im proved its absorption in the intestine.
An en capsulated f orm o f Aimpila™ ( 0.6 m g/day) w as used a s m onotherapy i n pa tients wit h m etastatic c olorectal cancer ( mCRC). m CRC w as ch osen b ecause co lon can cers have AFPR [19] , and it was known to have 76,8% mutations of the p53 [3] . 0.012 m g/day of t he atractyloside, or 1/m illionth of t he pig's ora l L D50= 25-100 m g/kg we re s upposed to be nontoxic within Aimpila™ [26] .
CT-scans b efore and af ter th e 8 w eeks o f tr eatment h as shown t hat 6 out of 12 m CRC pa tients (50% ) ha ve responded to a suboptimal dose of Aimpila™ [29] . Two (2) of these 6 patients have shown full reduction of metastasis, one (1) patient a 73% reduction of the size of his metastasis and three (3) patients were stabilized. No significant side effects, quick growt h inhibition a nd tumor re duction we re re ported in that human study. This could be attributed to the way metastases w ere treated by us ing a di rect a poptosis mode o f Aimpila™ action.
Breast, liver, lung, ova rian, s tomach, pros tate a nd ot her cancers a re AF PR-positive [19] a nd c ould pot entially be treated with Aimpila™.
The data provided here support the idea of t he necessity of th e r ight co mbination o f s pecific an d ef fective p arts t o form an an ticancer "m agic b ullet". This m eans a f eature which inevitably induces apoptosis in cancer cells and avoids potential m utation pa thways. In a ddition, a s econd fe ature should be added to deliver the drug only to cancer cells and internalize it for optimal results.
CONCLUSION
Aimpila™ m eets the necessary and sufficient conditions to b e co nsidered as an anticancer "m agic b ullet" b ecause o f its h igh s pecificity to A FPR-positive c ancer ce lls an d b ecause it in ternalizes a tractyloside th anks to th e A FPRmediated endocytosis. Moreover, it has high efficacy in killing cancer cells due to direct apoptosis inducer action.
